{
    "ticker": "PSCI",
    "name": "Processa Pharmaceuticals, Inc.",
    "description": "Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat unmet medical needs. Founded in 2017 and headquartered in Hanover, Maryland, PSCI specializes in the advancement of treatments for patients suffering from chronic and life-threatening conditions. The company's lead product candidate, PCS6422, is designed for the treatment of various cancers, with a focus on providing effective options for patients who have limited therapeutic alternatives. In addition to oncology, Processa is also exploring applications in infectious diseases, particularly with their proprietary formulation of an existing drug aiming to enhance efficacy and safety. With a strong commitment to scientific research and clinical development, Processa aims to expedite the delivery of novel therapies to healthcare providers and patients. The company is guided by a team of seasoned professionals with extensive experience in drug development, regulatory affairs, and commercialization strategies, positioning it well to navigate the complexities of the biopharmaceutical landscape. Processa's mission is to improve patient outcomes and quality of life through innovative medical solutions that address significant health challenges.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "Hanover, Maryland, USA",
    "founded": "2017",
    "website": "https://www.processapharmaceuticals.com",
    "ceo": "Dr. David Young",
    "social_media": {
        "twitter": "https://twitter.com/processapharma",
        "linkedin": "https://www.linkedin.com/company/processa-pharmaceuticals/"
    },
    "investor_relations": "https://www.processapharmaceuticals.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. David Young",
            "position": "CEO"
        },
        {
            "name": "Dr. Steven A. Frucht",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "PCS6422"
            ]
        },
        {
            "category": "Infectious Diseases",
            "products": [
                "Proprietary Formulation"
            ]
        }
    ],
    "seo": {
        "meta_title": "Processa Pharmaceuticals, Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, particularly in oncology and infectious diseases.",
        "keywords": [
            "Processa Pharmaceuticals",
            "Biopharmaceuticals",
            "Oncology",
            "Healthcare",
            "PCS6422"
        ]
    },
    "faq": [
        {
            "question": "What does Processa Pharmaceuticals focus on?",
            "answer": "Processa Pharmaceuticals focuses on developing innovative therapies for unmet medical needs in oncology and infectious diseases."
        },
        {
            "question": "Who is the CEO of Processa Pharmaceuticals?",
            "answer": "Dr. David Young is the CEO of Processa Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Processa Pharmaceuticals headquartered?",
            "answer": "Processa Pharmaceuticals is headquartered in Hanover, Maryland, USA."
        },
        {
            "question": "What is Processa's lead product candidate?",
            "answer": "Processa's lead product candidate is PCS6422, aimed at treating various cancers."
        },
        {
            "question": "When was Processa Pharmaceuticals founded?",
            "answer": "Processa Pharmaceuticals was founded in 2017."
        }
    ],
    "competitors": [
        "CLVS",
        "TGTX",
        "PBYI"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}